CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions
Authors:
- Christophe BlanquartCBChristophe Blanquart
- Fabien GueugnonFGFabien Gueugnon
- Jean-Michel NguyenJNJean-Michel Nguyen
- David RouloisDRDavid Roulois
- Laurent CellerinLCLaurent Cellerin
- Christine SaganCSChristine Sagan
- Christian PerigaudCPChristian Perigaud
- Arnaud ScherpereelASArnaud Scherpereel
- Marc GregoireMGMarc Gregoire
- 1 May 2012
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 7 (5) , 883-889
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Identification of Novel Markers for the Diagnosis of Malignant Pleural MesotheliomaThe American Journal of Pathology, 2011
- Biomarkers for Early Detection of Malignant Mesothelioma: Diagnostic and Therapeutic ApplicationCancers, 2010
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaEuropean Respiratory Journal, 2009
- Serum and pleural fluid biomarkers for mesotheliomaCurrent Opinion in Pulmonary Medicine, 2009
- Overexpression of protease inhibitor‐dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivoCancer Science, 2009
- Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cellsCancer Science, 2008
- Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesotheliomaThorax, 2007
- Soluble mesothelin-related protein—A blood test for mesotheliomaLung Cancer, 2005
- Epidemiology of malignant mesothelioma in AustraliaLung Cancer, 2004
- Clinical utility of biochemical markers in colorectal cancerEuropean Journal of Cancer, 2003